MedTrace Logo

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa

NCT01468207 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 307

Last updated 2021-07-07

Study results available
· View outcomes & findings →

Summary

A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

BIOLOGICAL

adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection

BIOLOGICAL

placebo

Placebo pre-filled syringe, administered by subcutaneous injection

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • David Williams, MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-01-31
Completion
2014-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468207 on ClinicalTrials.gov